Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial.

(2017) M. H. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours

(2014) E. Raymond et al.   Current Oncology

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors

(2012) L. Sideris et al.   ONCOLOGIST

New targeted agents in gastroenteropancreatic neuroendocrine tumors

(2012) Marta Benavent et al.   Targeted Oncology

Somatostatin analogs for the treatment of neuroendocrine tumors

(2011) Michael D. Culler et al.   CANCER AND METASTASIS REVIEWS

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETS)

(2011) Rocío García-Carbonero et al.   Clinical & Translational Oncology

The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

(2011) Ben Lawrence et al.   ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA

6630 POSTER Evaluation of the Efficacy and the Safety of Lanreotide on Tumour Growth Stabilization in Patients With Progressive Neuroendocrine Tumours (NETs) Who Are Not Eligible to Be Treated With Either Surgery or Chemotherapy – TTD Group Study

(2011) B. Massuti et al.   EUROPEAN JOURNAL OF CANCER

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)

(2011) John K Ramage et al.   GUT

Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy

(2011) Corinne Bousquet et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group

(2010) W. Kocha et al.   Current Oncology

NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors

(2010) Alexandria T. Phan et al.   PANCREAS

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

(2009) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY